Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Actinium Pharmaceuticals, Inc. regarding a class action lawsuit related to misleading statements and omissions concerning the company's drug approval process [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from October 31, 2022, to August 2, 2024 [3]. - Allegations include that the company made materially false and misleading statements about the Phase 3 Sierra trial data, which was unlikely to meet FDA guidelines for the approval of the targeted radiotherapy, Iomab-B BLA [3]. - Additional analyses provided to the FDA were also claimed to be insufficient to mitigate the poor overall survival data from the Sierra trial [3]. - As a result, it is alleged that the FDA would likely refuse to review the Iomab-B BLA or that the application would not be approved in its current form [3]. - The defendants' positive statements regarding the company's business and prospects were deemed materially misleading [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by May 27, 2025, to participate in the case without any cost or obligation [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].